|
|
|
| Progress in prevention and management of mucormycosis |
| ZHAO Jingyu1，2, FANG Wei1, PAN Weihua1, LIAO Wanqing1 |
| 1. Shanghai Key Laboratory of Molecular Medical Mycology, Department of Dermatology, Shanghai Changzheng Hospital, Shanghai 200003, China; 2. Department of Dermatology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China |
|
|
|
| Guide |
|
|
Abstract Mucormycosis is a rare invasive fungal disease with rapid progress and high fatality rate. In the past years, its incidence has shown an upward trend. Since December 2019, the corona virus disease 2019 (COVID-19) epidemic has been widespread worldwide and triggered the sixth international public health event. In this context, a large-scale outbreak of mucormycosis has occurred in India. This article reviewed the progress in the epidemiology, etiology, clinical manifestations, and diagnosis and treatment principles of mucormycosis. For the patients with suspected mucormycosis, imaging, fungal etiology, and molecular biological examinations should be completed as soon as possible, which are vital to realize early diagnosis and treatment and improve their clinical outcomes and prognosis.
|
|
Received: 15 June 2021
Published: 25 October 2021
|
|
|
| Fund: |
|
Corresponding Authors:
LIAO Wanqing
E-mail: liaowanqing@sohu.com
|
|
|
|
|
|
|
2021, Vol. 16 
